Special populations- What makes them so special? AGAH Association for Applied Human Pharmacology Annual meeting 2004 Berlin 29. Februar 2004 Birka Lehmann.

Slides:



Advertisements
Similar presentations
SARQA/DKG Conference 3-4 October SARQA/DKG Conference 3-4 OCTOBER 2002 Annex 13 Update An Industry Perspective Michael J Cooke Director, Global.
Advertisements

Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
International Clinical Trials: Current Issues in Clinical Trial Regulation and Future Reforms: EU, US, and Beyond: a European perspective International.
1 European Commission Taxation and Customs Union European Commission Taxation and Customs Union.
The European Citizens Initiative Introduction Legal framework Rules and procedures The procedure at a glance Current state of play Further information.
1 European Commission The role of regional networks in the EU policy making process Disclaimer: This contains the personal opinions of the author.
1 European Commission, DGENV.D. 3 Strategic Environmental Assessment Directive 2001/42/EC on the assessment of the effects of certain plans and programmes.
THE CERTIFYING AUTHORITY
Introduction to Article 45 (5) of the CLP Regulation
Management and control systems Franck Sébert, DG Regional and Urban Policy, Head of Unit C1 SEVENTEENTH MEETING OF THE EXPERT GROUP ON.
Good Clinical Practice in Research Clinical Trial Regulations
Timelines Trust informed June 2007
Cultural Goods 6 th April Relevant Acquis Icelandic Legislation International Conventions Application Form for Export Structure & Responsibility.
Safety Reporting IN Clinical Trials
WHO update on: Guidelines for the selection of RH medicines and prequalification of priority RH medicines Medicines Policy and Standards Health Technology.
ROLE OF THE PHYSICIAN IN THE APPROVAL PROCESS Stephanie de Bono MD PhD Medical Advisor, Eli Lilly.
1 The Data Protection Officer at work Experience, good practices and lessons learnt Pierre Vernhes – former DPO at the Council of the EU Workshop on Data.
HOT TOPICS ARCHIVING OR HOW NOT TO DUMP YOUR RUBBISH!
Center for Clinical Research - Clinical Trials Center (CTC) Clinical Research and Clinical Trials in Switzerland Jürg Lustenberger, PhD Dipl. Pharm. Med.
1 Budapest, June 14, Cross border communication among registers - Practical aspects - Yves Gonner Managing director - Trade and Companies Register.
Disclaimer The presentation is intended for educational purposes only and does not replace independent professional judgement. Statements of fact and opinions.
Explosives Working Group 4 November 2014 Notified Bodies and NANDO Norma McGovern, DG ENTR.C1 – Internal Market and its International Dimension.
IMP/Placebo Sourcing, Release, Storage and Reconciliation. Ms Caroline Whiriskey Research Pharmacist, HRB Clinical Research Facility Galway.
Introduction to PPDs Regulatory requirements and rationale.
ICH GCP, the MHRA and PATHOLOGY PATHOLOGY QUALITY ASSURANCE Rob Wosley MRQA SEPTEMBER 2009.
Managing Sponsorship Research Services University of Oxford.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.
EORTC EU Clinical Trials Directives Organisation and Implementation of Cancer Clinical Trials Anastassia Negrouk EORTC Regulatory Affairs Manager Intergroup.
1 The Increasingly Important Role of US and EU Cooperation in GCP in Europe and Globally Steps toward Harmonization DHHS Secretary’s Advisory Committee.
Pharma.be The Initiative to Promote Clinical Trials in Belgium Key Performance Indicators: Impact on Clinical Research of European Legislation Square –
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
Investigational New Drug Application (IND)
Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.
EUNetPaS is a project supported by a grant from the EAHC. The sole responsibility for the content of this presentation lies with the author(s). The EAHC.
Jean Monnet Chair of EU Labour Law Academic Year Silvia Borelli:
Federal agency for medicines and health products EC REGULATION 1901/2006 ON MEDICINAL PRODUCTS FOR PAEDIATRIC USE AND HOMEOPATHIC MEDICINAL PRODUCTS Marie-Anne.
Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 1 WHO Training Workshop on Pharmaceutical Quality, Good Manufacturing Practice &
Twinning Project No 00MAC01/02/006: Approximation of Legislation to the Internal Market Acquis An EU-funded project managed by the European Agency for.
The New Legislative Framework
Good Clinical Practice (GCP) UKTMN 6 th June 2006.
Water.europa.eu Update on legal issues Strategic Coordination Group Update as of Marco Gasparinetti, DG ENV.D.1, European Commission.
Overcoming challenges in pediatric oncology product development: Regulatory oversight of multi-national clinical studies Ursula Kern, Advisory Committees.
New from 2013… to 2017 Declaration of Helsinki 2013 Updated definition of Critical Audit Finding from HRA April 2014 European Regulation 2014 Care Act.
TAIEX Workshop on the Implementation of EU Pharmacovigilance Legislation - BELGRADE CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 27 – Environment and Climate Change.
A little bit of history Directive 65/65/EC founds European pharmaceutical legislation but excludes medicines used for research purposes from.
Responsibilities of Sponsor, Investigator and Monitor
ICORD 2006 Kerstin Westermark Md, PhD, Assoc. prof. COMP Chairperson.
Off-label Use.
Agenda Vision Overview of Plain Language Summary
Periodic Safety Update Reports (PSUR)
Responsibilities of Sponsor, Investigator and Monitor
Nordic Cooperation on Ethical Review Procedures Nordforsk – nordic trial alliance MIKA SCHEININ
Information on Medicinal Products
MAINTAINING THE INVESTIGATOR’S SITE FILE
Regulation EU 536/2014 on clinical trials
EudraVigilance.
EudraCT V10 and the clinical trial regulation
Administering Informed Consent Issues for Discussion
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Pharmacovigilance in clinical trials
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
GCP Refresher for Investigators
EudraCT Public information on Clinical Trials - update
Multinational collaboration in the Authorisation of VMPs: the EU approach VICH Outreach Forum Tokyo, Nov 2017 Noel Joseph European Commission.
TAIEX, Istanbul, April 19th, 2011
International Clinical Trials
Interconnection of good practices: from development to distribution
Presentation transcript:

Special populations- What makes them so special? AGAH Association for Applied Human Pharmacology Annual meeting 2004 Berlin 29. Februar 2004 Birka Lehmann EUROPEAN COMMISSION Enterprise Directorate-General Pharmaceuticals Unit

Richtlinie 2001/20/EG DES EUROPÄISCHEN PARLAMENTS UND DES RATES Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001and published 1/5/2001

Directive 2001/20/EC Objectives: Protection of subjects participating in clinical trials Information on clinical trials - including database Single decision by competent authorities Single decision by Ethics Committees Good Manufacturing Practice (GMP) Good Clinical Practice (GCP)

Directive 2001/20/EC Article 22  Implementation in national legislation AT ? IR ? BE ? IT DK LU ? DE ? NL ? EL ? PO ? ES SE FI ? UK ? FR ?

Directive 2001/20/EC Article 1Good clinical practice → new Directive&Guideline Articles Ethics Committee → guidance Article 9Competent authorities → guidance Article 11Eudract database, Exchanges of information → guidance Article 13.1 Manufacturing/importation authorisation requirements for investigational medicinal products → new Directive&Guideline requirements for investigational medicinal products → new Directive&Guideline Article 15 Inspections (Inspection procedure, Qualification of inspector) and Master file on the trial and archiving → new Directive&Guideline Article 17 Eudravigilance database → guidance

Directive 91/356/EC replaced by  Directive 2003/94/EC of 8 October 2003  Directive 2003/94/EC of 8 October 2003 OJ L 262/  Annex 13  Annex 13 Manufacture of investigational medicinal products Manufacture of investigational medicinal products up-dated and published July 2003 up-dated and published July 2003 Directive on Good Manufacturing Practice

The interaction between the Ethics Committees, Competent Authority and Sponsor and in the European Medicinal Product Legislation – before starting a clinical trial SPONSOR Ethics Committee Start of the Trial Investigator/Applicnat Competent Authority

The interaction between the Ethics Committees, Competent Authority and Sponsor and in the European Medicinal Product Legislation - during conducting a clinical trial SPONSOR Ethics Committee Investigator Amendments/ end of trial suspension/ Adverse reactions Competent Authority Competent Authority Investigator Ethics Committee Competent Authority Investigator

Detailed guidance on the application format and documentation to be submitted in an application for an ethics committee opinion on a clinical trial on a medicinal product for human use Detailed guidance for the request for the authorisation of a clinical trial on a medicinal product for human use to the competent authorities in the European Union, notification of substantial amendments and clarification of the end of a clinical Detailed guidance on the collection, verification and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use Guidance published 23 April 2003 Commission web-site  under review

Directive 2001/20/EC and Guidance Documents   Harmonisation: Time-line for opinion by Ethics Committees (EC) Time-line for ‘authorisation’ by competent authorities (CA) Application Form to EC and CA Information on content of the dossier

Detailed guidance on the European clinical trial data base (Application form to EC and CA) Detailed guidance on the European database of Suspected Unexpected Serious Adverse Reactions Guidance published 23 April 2003 Commission web-site  under review

The European clinical trial data base & European database of Suspected Unexpected Serious Adverse Reactions European database

 Dataset requires for allocation of a EudraCT number  Minimum core dataset for EudraCT: 1 May 2004  Full acting system in place: 2005 European database  Pilot-phase finalised

 Dataset for Eudravigilance database  Definition of inclusion of information in Clinical Trials Database OR Pharmacovigilance database Trials Database OR Pharmacovigilance database for medicinal products with MA European database

 Directive 2001/20/EC = Member States, the Agency and the Commission ONLY  Regulation (EC) No …/2003/EC Article 57 (1) (k) creating a database on medicinal products to be accessible to the general public Article 57 (2) … Where appropriate, the database shall also include references to data on clinical trials currently carried out or already completed, contained in the clinical trials database for in Article 11 of Directive 2001/20/EC. The Commission shall, in consultation with the Member States, issue guidelines on data fields which could be included and which may be accessible to the public European database

Directive on Good Clinical Practice  Good Clinical Practice  Manufacture and import of investigational medicinal products medicinal products  Trial Master File and Archiving  Qualification of GCP inspectors  GCP Inspection procedures Directive/Guidelines  awaited

Directive 2001/20/EC   Concerns raised by academic and researchers Definition of Sponsor and responsibilities of the sponsor Requirements of GMP Bureaucraties

 Increased data requirements and application details compared to old system  but unified format and contents of application  Pharmacovigilance reporting system  different/selective approaches pointed out in guidance documents  Medicinal Product in accordance with Good Manufacturing Process  Patient need assurance of high quality of medicinal product Directive 2001/20/EC

Herzlichen Dank